B
CYCN icon

Braidwell’s Cyclerion Therapeutics CYCN Stock Holding History

Braidwell’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$532K Buy
+156,890
New +$509K 0.02% 86

Other funds holding CYCN

KCM
Kalehua Capital Management Dallas, Texas $140M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell's CYCN Position: Q2 2026 in Review

Braidwell opened a new position in Cyclerion Therapeutics (CYCN) in Q2 2026: 156,890 shares worth $532K. The stake represents 0.02% of the portfolio and ranks #86 among its holdings.

21 funds tracked by Wall St. Rank hold CYCN as of Q2 2026.

  • Braidwell held 156,890 shares of Cyclerion Therapeutics worth $532K as of Q2 2026.
  • Cyclerion Therapeutics was a new Braidwell position in Q2 2026.
  • Cyclerion Therapeutics made up 0.02% of Braidwell's portfolio in Q2 2026, its #86 holding.
  • 21 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.